Technology Bundle ID: TAB-2819

A Device for Simultaneous and Rapid Diagnosis and Detection of Recent and Long Term HIV-1 Infection

Request More Info
Licensing Contact:
Primary Inventors: 
Timothy Granade (CDC)
Co-Inventors: 
Chou-Pong Pau (CDC), Steve McDougal (CDC)
Development Stage: 
Prototype
Development Status: 
  • Early-stage
  • Prototype
Institute or Center: 
CDC

CDC scientists have developed a device for simultaneous rapid diagnosis of HIV infection and for identification of recent HIV-1 infection. The device utilizes immunochromatographic or flow-through principles to detect HIV antibodies within clinical samples. This device may be used for diagnosis of HIV infection, as well as to distinguish between recent infection (1 year). This latter application has added significance for surveillance, counseling, partner notification and other related prevention concerns, including the estimation of HIV incidence in cross-sectional populations. The device, if formatted as a self-contained kit, would utilize a single platform containing all required reagents, making it simple and easy for use by minimally trained technicians. The entire testing process, including the determination of incident infections, has been designed to minimize assay processing time. This device has potential as an important tool for regional incidence measurements, which can aid targeting of prevention activities and allocation of resources by HIV/AIDS prevention programs, as well as serve as an indicator of the effectiveness of intervention strategies.

Applications:
  • Routine HIV screening and diagnostics
  • Establishment of a specific "window-of-infection" timeframe
  • HIV/AIDS surveillance programs and evaluation of prevention program effectiveness
  • Identification of high-risk cohorts for vaccine development, microbicide research and targeting resources
  • HIV/AIDS research tool
  • Screening tool for emergency blood donation
Advantages:
  • Simple, single platform testing
  • Greater cost efficiency than current immunoassays in terms of resource input and labor investment
  • Exceptionally rapid assay processing
  • Permits early-as-possible diagnosis, counseling, partner notification and early treatment
  • Assay can be developed for on-site testing, at-home use or resource-limited environments using finger prick blood samples

Patents

EIR Application

Research Tool – Patent protection is not being pursued for this technology.

Research Tools – Patent protection is not being pursued for these technologies.

Publications

Granade TC.
PMID 23281586

Updated

May 15, 2014

Data Source: 
tts